Swiss National Bank
SION

Swiss National Bank’s Sionna Therapeutics SION Stock Holding History

Swiss National Bank’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
+27,000
New +$1.08M ﹤0.01% 2166

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Swiss National Bank's SION Position: Q2 2026 in Review

Swiss National Bank opened a new position in Sionna Therapeutics (SION) in Q2 2026: 27,000 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #2166 among its holdings.

147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Swiss National Bank held 27,000 shares of Sionna Therapeutics worth $1.19M as of Q2 2026.
  • Sionna Therapeutics was a new Swiss National Bank position in Q2 2026.
  • Sionna Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2166 holding.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.